Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, has announced the completion of patient dosing in the Phase 2 portion of their Phase 2/3 RePOSA study evaluating IHL-42X, an oral once-daily treatment for obstructive sleep apnea (OSA). The end-of-study follow-up assessments are on track to conclude by May 17, 2025, with topline results expected in July 2025. The company is preparing for an end-of-Phase 2 meeting with the FDA, marking a pivotal period in advancing IHL-42X as a potential first-in-class oral treatment for millions affected by OSA. Phase 3 of the study is set to be conducted exclusively in the United States, with plans to recruit 440 patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.